Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?

Royalty Pharma (RPRX) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by improving business fundamentals and positive earnings estimate revisions.